Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 2,286 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Open Label Extension Clear all
Completed Phase 3 Interventional Results available

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

NCT00097695
View directory record Official record
Conditions
Angioedema
Interventions
Icatibant, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis

NCT01976364
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Tofacitinib, Methotrexate, Placebo Methotrexate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
686 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
43
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated May 21, 2020 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 2 Interventional Results available

OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension

NCT01642212
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Oral Budesonide Suspension (MB-9), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 40 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
23
States / cities
Phoenix, Arizona • Orange, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2021 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

NCT04533529
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Seltorexant, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 74 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
51
States / cities
Anaheim, California • Cerritos, California • Irvine, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 26, 2026, 10:55 AM EDT
Terminated Phase 3 Interventional

An Open-Label Extension Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy

NCT03917719
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Edasalonexent
Drug
Lead sponsor
Catabasis Pharmaceuticals
Industry
Eligibility
4 Years to 12 Years · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
15
States / cities
Sacramento, California • Atlanta, Georgia • Iowa City, Iowa + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced Oct 26, 2026, 10:55 AM EDT
Not listed Phase 3 Interventional

Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH

NCT02652429
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
Not listed
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 26, 2026, 10:55 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity

NCT04815967
View directory record Official record
Conditions
Spasticity, Cerebrovascular Accident, Multiple Sclerosis, Traumatic Brain Injury, Cervical Spinal Cord Injury, Cerebral Palsy
Interventions
Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo, Phase 3; MYOBLOC, Phase 3; Placebo
Drug
Lead sponsor
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
Downey, California • Boise, Idaho • Port Royal, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Early Phase 1 Interventional Results available

An Open-Label and Long-Term Extension Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Patients With Ichthyoses

NCT04549792
View directory record Official record
Conditions
Ichthyosis
Interventions
Ustekinumab
Drug
Lead sponsor
Northwestern University
Other
Eligibility
6 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors

NCT02847637
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, Factor VIII (FVIII)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
8
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.

NCT00594165
View directory record Official record
Conditions
Early-Stage Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
31 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
37
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03653026
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Placebo, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
16 Years to 75 Years
Enrollment
522 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
114
States / cities
Mobile, Alabama • Sun City, Arizona • Tempe, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome

NCT03995108
View directory record Official record
Conditions
WHIM Syndrome
Interventions
Mavorixafor, Placebo
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
6
States / cities
San Diego, California • Thousand Oaks, California • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

NCT04887870
View directory record Official record
Conditions
Advanced or Metastatic Solid Malignancies
Interventions
Sitravatinib, Nivolumab, Pembrolizumab, Enfortumab Vedotin-Ejfv, Ipilimumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
13
States / cities
Littleton, Colorado • Goshen, Indiana • Boston, Massachusetts + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of Oxycodone Hydrochloride and Naltrexone Hydrochloride Extended-Release Capsules in Subjects With Moderate to Severe Chronic Noncancer Pain

NCT01428583
View directory record Official record
Conditions
Chronic Noncancer Pain
Interventions
oxycodone HCl and naltrexone HCl extended-release capsules
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
32
States / cities
DeLand, Florida • Jacksonville, Florida • Jupiter, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets for Moderate to Severe Chronic Low Back Pain

NCT01789970
View directory record Official record
Conditions
Low Back Pain
Interventions
Hydrocodone ER, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
87
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2017 · Synced Oct 26, 2026, 10:55 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension

NCT04271475
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension
Interventions
Macitentan, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
24
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2025 · Synced Oct 26, 2026, 10:55 AM EDT
Recruiting Phase 3 Interventional

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

NCT06807281
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
2 Years to 11 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
11
States / cities
Birmingham, Alabama • North Little Rock, Arkansas • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 4 Interventional Results available

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

NCT01573572
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
pegaptanib sodium injection
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2021 · Synced Oct 26, 2026, 10:55 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

NCT05681481
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
efgartigimod PH20 SC, Prednisone
Biological · Drug
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Phoenix, Arizona • Fountain Valley, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 3 Interventional Results available

Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain

NCT00415597
View directory record Official record
Conditions
Pain
Interventions
ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
58
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 26, 2026, 10:55 AM EDT
Recruiting Phase 3 Interventional

A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand Disease

NCT06998524
View directory record Official record
Conditions
Von Willebrand Disease, Type 3
Interventions
Emicizumab, von Willebrand Factor (VWF) Concentrates, Factor VIII (FVIII) Concentrates, von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates, Bypassing Agents
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
1 Month and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
Sacramento, California • Gainesville, Florida • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 26, 2026, 10:55 AM EDT
Recruiting Phase 2 Interventional

A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder

NCT06809179
View directory record Official record
Conditions
Social Anxiety Disorder
Interventions
Fasedienol Nasal Spray - Placebo Nasal Spray, Fasedienol Nasal Spray - Fasedienol Nasal Spray, Placebo Nasal Spray - Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Sherman Oaks, California • Walnut Creek, California • Largo, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 26, 2026, 10:55 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Soticlestat in Adults and Children With Rare Epilepsies

NCT03635073
View directory record Official record
Conditions
Epilepsy, Dravet Syndrome (DS), Lennox-Gastaut Syndrome (LGS)
Interventions
Soticlestat
Drug
Lead sponsor
Takeda
Industry
Eligibility
2 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 26, 2026, 10:55 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

NCT02851212
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC], Canagliflozin, Metformin Extended Release (XR)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Oct 26, 2026, 10:55 AM EDT